Zoetis Inc.
Zoetis Raises Full Year 2024 Guidance Following Strong Second Quarter
Summary
Zoetis Inc. reported its financial results for the second quarter of 2024, showing an 8% increase in revenue and a 7% decrease in net income on a reported basis. The company also raised its full-year 2024 revenue guidance to a range of $9.100 to $9.250 billion and adjusted its diluted EPS guidance to a range of $5.78 to $5.88. Operationally, Zoetis achieved 11% revenue growth and 18% growth in adjusted net income. The company attributed its strong performance to robust demand for its products and improved operational efficiency.
Profitelligence Alerts
Get alerts for ZTS
Be first to know when Zoetis Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Zoetis Inc.
Zoetis Inc. is a global leader in the animal healthcare sector, specializing in the development, manufacture, and commercialization of a diverse range of medicines and vaccines for pets and livestock. Originally part of Pfizer, Zoetis spun off in 2013 and has solidified its position as a key player in the industry. The company's portfolio includes products aimed at veterinarians and livestock producers, supporting health and productivity across various animal species. Zoetis's impact is significant in both the companion animal market, which is driven by increasing pet ownership and rising expenditure on pet care, and the livestock market, which benefits from enhancements in productivity and disease management. Zoetis operates in over 100 countries, continuously investing in research and innovation to address the evolving needs of animal health. Its strategic initiatives and partnerships contribute to building a sustainable future for the animal health industry, bolstering Zoetis’s reputation and relevance in the global market.
Official SEC Documents
Advertisement